Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Int J Cardiol ; 221: 422-7, 2016 Oct 15.
Article in English | MEDLINE | ID: mdl-27409567

ABSTRACT

UNLABELLED: Abnormal liver function tests (LFTs) are a common manifestation of heart failure (HF). Our purpose was to characterize patients hospitalized for acute HF (AHF) with liver cytolysis, analyze cytolysis predictors and explore its prognostic implications. METHODS: In a prospective cohort study, we enrolled patients with AHF consecutively admitted to the Internal Medicine Department of University Hospital between January 2009 and December 2010, and recorded demographic, clinical, laboratory and echocardiogram parameters. A logistic regression was done to identify cytolysis predictors. In survival analysis primary endpoints were all-cause death, readmission due to AHF, and the combined event of all-cause death and readmission for AHF at 90days of follow-up. RESULTS: Fifty-eight patients had cytolysis at admission. AHF attributed to atrial fibrillation (OR 3.235), higher heart rate at admission (OR 1.028), cold/wet profile at admission (OR 7.12) and ejection fraction <30% (OR 2.316) were independent predictors of cytolysis. Death occurred more frequently during follow-up in the cytolysis group (27.6 vs. 15.1%, p=0.014, respectively). On survival analysis, cytolysis remained an independent predictor of death at 90days when adjusted to age (HR 1.066), male gender (HR 1.884), valvular etiology (HR 2.365), neurologic status at admission (sleepy HR 3.854; confusion HR 3.176) and cardiac output (HR 0.762). CONCLUSION: Cytolysis may be a marker of systemic hypoperfusion, so strategies to improve hemodynamic profile should be considered, especially in the presence of cold/wet clinical profile, AHF attributed to AF, tachycardia, and EF<30%. Cytolysis is associated with higher mortality at 90days in patients with AHF.


Subject(s)
Heart Failure/blood , Heart Failure/diagnosis , Hospitalization/trends , Liver Diseases/blood , Liver Diseases/diagnosis , Acute Disease , Aged , Aged, 80 and over , Cohort Studies , Female , Follow-Up Studies , Heart Failure/epidemiology , Humans , Liver Diseases/epidemiology , Liver Function Tests/methods , Liver Function Tests/trends , Male , Middle Aged , Prospective Studies , Treatment Outcome
3.
J Cardiovasc Pharmacol Ther ; 21(5): 466-70, 2016 09.
Article in English | MEDLINE | ID: mdl-26940569

ABSTRACT

PURPOSE: There is a lack of knowledge on the effects of nitrates alone in heart failure (HF). We aimed to assess the impact of nitrates use in the occurrence of ischemic events in patients with ischemic HF attending an HF clinic. METHODS: We performed a retrospective analysis of a cohort of 632 patients managed in an HF clinic between January 2000 and December 2011. Patients with ischemic etiology were selected (n = 290). Patients were classified according to chronic nitrates use (n = 83 nitrates users vs n = 194) and followed up for 5 years for the occurrence of fatal or nonfatal myocardial infarction or stroke. RESULTS: Nitrates users had more frequently diabetes, dyslipidemia, and higher body mass index but were less frequently treated with statins. Thirty adverse events were recorded (n = 16 in nitrates group). Variables significantly associated with the occurrence of the end point in univariate analysis were arterial hypertension, diabetes, and nitrates use. Male gender, beta-blockers, statin, and clopidogrel use had a protective effect on the occurrence of the end point. In multivariate analysis, nitrates use remained an independent predictor of adverse outcome when adjusted for each of the variables: arterial hypertension, gender, diabetes, beta-blocker, and clopidogrel use; however, when adjusted for statin use, nitrates were no longer associated with the outcome. CONCLUSION: Long-term nitrates use in patients with ischemic HF was associated with higher occurrence of ischemic events, defined as fatal or nonfatal myocardial infarction or stroke. Our results, although from a retrospective analysis, do not support a role for chronic nitrate use in HF.


Subject(s)
Heart Failure/drug therapy , Myocardial Ischemia/drug therapy , Nitrates/administration & dosage , Vasodilator Agents/administration & dosage , Aged , Chi-Square Distribution , Drug Administration Schedule , Female , Heart Failure/diagnosis , Heart Failure/mortality , Heart Failure/physiopathology , Humans , Kaplan-Meier Estimate , Male , Multivariate Analysis , Myocardial Infarction/mortality , Myocardial Ischemia/diagnosis , Myocardial Ischemia/mortality , Myocardial Ischemia/physiopathology , Nitrates/adverse effects , Proportional Hazards Models , Retrospective Studies , Risk Factors , Stroke/mortality , Time Factors , Treatment Outcome , Vasodilator Agents/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...